Issued 17 July 2023

Novo Nordisk Limited, Ireland wishes to advise of a stock shortage of NovoRapid® (insulin aspart) 100 units/ml solution for injection in vial, which is used to reduce high blood sugar levels in patients with diabetes mellitus.

A return to stock is expected in early August 2023. This shortage is due to manufacturing delays and is not a result of any quality or safety issues.

Healthcare Professionals have been informed of this shortage.

Advice for patients prescribed NovoRapid® (insulin aspart) 100 units/ml solution for injection in vial

• Patients at risk of running out of NovoRapid® vial are advised to contact their prescriber without delay and be switched to an alternative bolus insulin delivery device or bolus insulin.
• Do not stop taking NovoRapid® vial or change your treatment unless agreed with your Healthcare Professional as this may result in high blood sugar levels (shown in tests) and high levels of ketones.

Reporting of side effects

Adverse events including medication errors relating to NovoRapid® or alternative Novo Nordisk products should be reported to Novo Nordisk Limited, Ireland at [email protected] or tel: 01 8629700, or to the HPRA at www.hpra.ie.

Company contact point

Further information can be obtained by contacting Novo Nordisk Limited, Ireland on 01 8629700 or [email protected].